Insulinotropic actions of the frog skin host-defense peptide alyteserin-2a: A structure-activity study

Chemical Biology and Drug Design

Volumn 82, Issue 2, 2013, Pages 196-204

  Ojo, Opeolu O ^a   Abdel Wahab, Yasser H A ^a   Flatt, Peter R ^a   Conlon, J Michael ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Alyteserin 2a; Insulin releasing activity; Structure activity; Type 2 diabetes

Indexed keywords

DEXTRO LYSINE; ISOLEUCYLLEUCYLGLYCYLLYSYLLEUCYLLEUCYLSERYLTHREONYLALANYLALANYLGLYCYLLEUCYLLEUCYLSERYLASPARAGINYLLEUCINE AMIDE; LACTATE DEHYDROGENASE; LYSINE; PEPTIDE; TRYPTOPHAN; UNCLASSIFIED DRUG;

AMPHIPATHICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CELL MEMBRANE; CHEMICAL PARAMETERS; CONTROLLED STUDY; GLUCOSE TOLERANCE; HOST RESISTANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; LIPID DIET; MALE; MEMBRANE DEPOLARIZATION; MOUSE; NONHUMAN; OBESITY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ALYTESERIN-2A; INSULIN-RELEASING ACTIVITY; STRUCTURE-ACTIVITY; TYPE 2 DIABETES;

AMINO ACID SEQUENCE; AMPHIBIAN PROTEINS; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CALCIUM; CELL LINE; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; MALE; MICE; MOLECULAR SEQUENCE DATA; OBESITY; RANIDAE;

ANURA; MUS;

EID: 84880751380     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12151     Document Type: Article

References (33)

1. Conlon J.M. (2011) The contribution of skin antimicrobial peptides to the system of innate immunity in anurans. Cell Tissue Res;343:201-212.
2. Giuliani A., Pirri G., Bozzi A., Di Giulio A., Aschi M., Rinaldi A.C. (2008) Antimicrobial peptides: natural templates for synthetic membrane-active compounds. Cell Mol Life Sci;65:2450-2460.
3. Popovic S., Urbán E., Lukic M., Conlon J.M. (2012) Peptides with antimicrobial and anti-inflammatory activities that have therapeutic potential for treatment of acne vulgaris. Peptides;34:275-282.
4. Lu C.X., Nan K.J., Lei Y. (2008) Agents from amphibians with anticancer properties. Anticancer Drugs;19:931-939.
5. Nasrollahi S.A., Taghibiglou C., Azizi E., Farboud E.S. (2012) Cell-penetrating peptides as a novel transdermal drug delivery system. Chem Biol Drug Des;80:639-646.
6. Ojo O.O., Flatt P.R., Abdel-Wahab Y.H.A., Conlon J.M. (2013) Insulin-releasing peptides. In: Kastin A.J., editor. Handbook of Biologically Active Peptides. San Diego, CA: Elsevier; p. 364-370.
7. Ojo O.O., Abdel-Wahab Y.H., Flatt P.R., Mechkarska M., Conlon J.M. (2011) Tigerinin-1R: a potent, non-toxic insulin-releasing peptide isolated from the skin of the Asian frog, Hoplobatrachus rugulosus. Diabetes Obes Metab;13:1114-1122.
8. Abdel-Wahab Y.H., Power G.J., Flatt P.R., Woodhams D.C., Rollins-Smith L.A., Conlon J.M. (2008) A peptide of the phylloseptin family from the skin of the frog Hylomantis lemur (Phyllomedusinae) with potent in vitro and in vivo insulin-releasing activity. Peptides;29:2136-2143.
9. Conlon J.M., Power G.J., Abdel-Wahab Y.H., Flatt P.R., Jiansheng H., Coquet L., Leprince J., Jouenne T., Vaudry H. (2008) A potent, non-toxic insulin-releasing peptide isolated from an extract of the skin of the Asian frog, Hylarana guentheri (Anura: Ranidae). Regul Pept;151:153-159.
10. Abdel-Wahab Y.H., Patterson S., Flatt P.R., Conlon J.M. (2010) Brevinin-2-related peptide and its [D4K] analog stimulate insulin release in vitro and improve glucose tolerance in mice fed a high fat diet. Horm Metab Res;42:652-656.
11. Conlon J.M., Demandt A., Nielsen P.F., Leprince J., Vaudry H., Woodhams D.C. (2009) The alyteserins: two families of antimicrobial peptides from the skin secretions of the midwife toad Alytes obstetricans (Alytidae). Peptides;30:1069-1073.
12. Schiffer M., Edmundson A.B. (1967) Use of helical wheels to represent the structures of proteins and to identify segments with helical potential. Biophys J;7:121-135.
13. McClenaghan N.H., Flatt P.R. (1999) Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diabetes Obes Metab;1:137-150.
14. McClenaghan N.H., Barnett C.R., Ah-Sing E., Abdel-Wahab Y.H.A., O'Harte F.P.M., Yoon T.-W., Swanston-Flatt S.K., Flatt P.R. (1996) Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes;45:1132-1140.
15. Flatt P.R., Bailey C.J. (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia;20:573-577.
16. Abdel-Wahab Y.H., Marenah L., Flatt P.R., Conlon J.M. (2007) Insulin releasing properties of the temporin family of antimicrobial peptides. Protein Pept Lett;14:702-707.
17. Miguel J.C., Patterson S., Abdel-Wahab Y.H., Mathias P.C., Flatt P.R. (2004) Time-correlation between membrane depolarization and intracellular calcium in insulin secreting BRIN-BD11 cells: studies using FLIPR. Cell Calcium;36:43-50.
18. Zasloff M. (1987) Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA;84:5449-5453.
19. Yang H., Wang X., Liu X., Wu J., Liu C., Gong W., Zhao Z., Hong J., Lin D., Wang Y., Lai R. (2009) Antioxidant peptidomics reveals novel skin antioxidant system. Mol Cell Proteomics;8:571-583.
20. Salmon A.L., Cross L.J., Irvine A.E., Lappin T.R., Dathe M., Krause G., Canning P., Thim L., Beyermann M., Rothemund S., Bienert M., Shaw C. (2001) Peptide leucine arginine, a potent immunomodulatory peptide isolated and structurally characterized from the skin of the Northern Leopard frog, Rana pipiens. J Biol Chem;276:10145-10152.
21. Conlon J.M., Mechkarska M., Pantic J.M., Lukic M.L., Coquet L., Leprince J., Nielsen P.F., Rinaldi A.C. (2013) An immunomodulatory peptide related to frenatin 2 from skin secretions of the Tyrrhenian painted frog Discoglossus sardus (Alytidae). Peptides;40:65-71.
22. Flatt P.R., Bailey C.J., Green B.D. (2009) Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab;10:125-137.
23. Fonseca V.A., Zinman B., Nauck M.A., Goldfine A.B., Plutzky J. (2010) Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. Am J Med;123:S2-S10.
24. Srinivasan D., Mechkarska M., Abdel-Wahab Y.H., Flatt P.R., Conlon J.M. (2013) Caerulein precursor fragment (CPF) peptides from the skin secretions of Xenopus laevis and Silurana epitropicalis are potent insulin-releasing agents. Biochimie;95:429-435.
25. Abdel-Wahab Y.H., Power G.J., Ng M.T., Flatt P.R., Conlon J.M. (2008) Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue. Biol Chem;389:143-148.
26. Conlon J.M., Mechkarska M., Arafat K., Attoub S., Sonnevend A. (2012) Analogues of the frog skin peptide alyteserin-2a with enhanced antimicrobial activities against Gram-negative bacteria. J Pept Sci;18:270-275.
27. Conlon J.M., Mechkarska M., Prajeep M., Arafat K., Zaric M., Lukic M.L., Attoub S. (2013) Transformation of the naturally occurring frog skin peptide, alyteserin-2a into a potent, non-toxic anti-cancer agent. Amino Acids;44:715-723.
28. Kim J.H., Lee J.O., Jung J.H., Lee S.K., You G.Y., Park S.H., Kim H.S. (2010) Gaegurin-6 stimulates insulin secretion through calcium influx in pancreatic beta Rin5mf cells. Regul Pept;159:123-128.
29. MacDonald P.E., Wheeler M.B. (2003) Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets. Diabetologia;46:1046-1062.
30. Islam M.S., du Loots T. (2009) Experimental rodent models of type 2 diabetes: a review. Methods Find Exp Clin Pharmacol;31:249-261.
31. Zhang H.J., Zhou F., Ji B.P., Li B., Luo Y.C., Yu H.Q., Zhang G.Z. (2009) Effects of fructose and/or fat in the diet on developing the type 2 diabetic-like syndrome in CD-1 mice. Horm Metab Res;41:40-45.
32. Fineman M.S., Mace K.F., Diamant M., Darsow T., Cirincione B.B., Booker Porter T.K., Kinninger L.A., Trautmann M.E. (2012) Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab;14:546-554.
33. Rossi M.C., Nicolucci A. (2009) Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. Acta Biomed;80:93-101.